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INTRODUCTION
Although the fetus is semiallograft to the mother’ s immune
system, a maternal immune tolerance to the fetus takes place
instead of immune rejection response (1). Since placenta is
the main site of maternal-fetal interaction, it should play an
immunosuppressive role for the maintenance of its villous
structures. When the maternal-fetal immune interaction be-
comes pathologic as in pregnancies complicated with pree-
clampsia and intrauterine growth restriction, however, in-
creased apoptosis in placenta has been reported (2, 3).
The Fas-Fas ligand (FasL) system is one of the major path-
ways for the induction of apoptosis in cells and tissues (4). Fas
(CD95) is a type I membrane protein of 45 kDa that belongs
to the tumor necrosis factor (TNF) superfamily and FasL, a
type II membrane protein of 42 kDa, belongs to the TNF
and CD40 ligand family. Fas has been reported to be expressed
widely in many tissues, in T and B cells and in human tro-
phoblast throughout gestation (5). Although Fas is present
constitutively on the surface of resting cells in low levels, its
expression is enhanced after lymphocyte activation (4). On
the other hand, FasL promotes apoptosis of activated Fas-bear-
ing lymphocytes and has been thought to confer immune
privilege in the anterior chamber of the eye (6), Sertoli cells
of the testis (7), and placenta (8).
Although Fas-FasL system may play a role in maintain-
ing human pregnancy, aberrant activation of this system in
trophoblast, the major cell type at the maternal-fetal interface
of placenta, may invoke pathologic changes in placenta. In
this study, we examined the distribution of Fas and FasL in
human placenta throughout gestation. Moreover, we investi-
gated changes in the expression of Fas and FasL in trophoblasts
isolated from human term placenta during their differentia-
tion in vitro.
MATERIALS AND METHODS
Placentas were obtained from women who underwent elec-
tive abortion from medical problems in first trimester (n=5)
and second trimester (n=5), and women (n=22) who delivered
at term without obstetric or medical complication. Immedi-
ately after delivery, about 10 g of placental tissues was collect-
ed from the maternal-fetal interface and washed in saline.
All samples were snap frozen in liquid nitrogen and stored
at -70℃ until further usage.
RT-PCR
Total RNA was extracted from each of the frozen tissues in
Trizol
� (Gibco-BRL, U.S.A.) as recommended by the manu-
facturer and reverse transcripted with 0.5  g Oligo (dT) 12-
18, 5×RT buffer, 1 mM dNTP, 1 U Rnasin, and 1  g Molo-
ney murine leukemia virus reverse transcriptase in a final
volume of 20  L. The synthesized first strand cDNA was
mixed into reaction cocktail (10×Buffer, 1 mM dNTP, 0.25
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Differential Expressions of Fas and Fas Ligand in Human Placenta 
To investigate the expressions of Fas and Fas ligand (FasL) in human placenta,
we studied the expressions of Fas and FasL in placenta with RT-PCR, immunoblot-
ting and immunostaining. We observed amplified products of Fas and FasL tran-
scripts, the band of Fas (52 kDa) and multiple bands of FasL (42-52 kDa) in pla-
centa. Fas and FasL localized mainly on fetal vessels and on syncytiotrophoblasts
respectively. The differential distribution of Fas and FasL in human placenta may
reflect intrinsic expressions of them by trophoblasts during differentiation. The in-
creased expression of Fas in trophoblasts may promote apoptosis of placenta in
pathologic condition such as preeclampsia.
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pM 5′ primer, 0.25 pM 3′ primer, 2.5 U Taq DNA polyme-
rase, and distilled water in a final volume of 40  L) for PCR
amplification. The primers for Fas, FasL, and GAPDH were
as follows, Fas (5′ -GAAGGACATGGCTTAGAAGTG and
3′ -ACTTAGTGTCATGACTCCAGC), FasL (5′ -TCTCAGA
CGTTTTTCGGCTT and 3′ -AAGACAGTCCCCCTTGAG
GT), and GAPDH (5′ -TGAAGGTCGGAGTCAACG GAT
TTGGT and 3′ -CATGTGGGCCATGAGGTCCAC CAC).
PCR was performed in thermal cycler for 30 cycles: anneal-
ing for 45 sec at 60℃, extension for 45 sec at 72℃, and de-
naturation for 30 sec at 94℃. For internal control, GAPDH
primers were put into the reaction mixture along with Fas or
FasL primers. PCR products were visualized on 2% agarose
gel.
Western blotting and Immunoprecipitation
Each placental tissues were disrupted in RIPA buffer (50
mM TrisCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxy-
cholate, 0.1% SDS, pH 7.5) containing 10 mM phenylmethyl-
sulfonyl fluoride. After centrifugation, protein concentrations
were determined for supernatants and 20  g of proteins were
separated on 10% (w/v) SDS-PAGE under reducing condi-
tion. After electrotransfer onto polyvinyldifluoride membrane,
the blots were blocked overnight at 4℃ in 5% nonfat dry
milk in TBS-T buffer. The blots were incubated for 1 hr at
room temperature with 1:500 diluted either mouse mono-
clonal anti-FasL antibody, G247-4 (Pharmingen, U.S.A.) or
rabbit polyclonal anti-Fas antibody, Fas (Ab-1) (Oncogene
Research Products, U.S.A.) in Tris-buffered saline-Tween20
(TBS-T) buffer. After washing, membranes were incubated
with peroxidase-conjugated secondary antibody at dilution
of 1:2,000 for 1 hr at room temperature. The reaction was
visualized using ECL western blotting kit (Amersham, U.K.).
To confirm the presence of Fas in placenta, placental tissue
lysates were subjected to immunoprecipitation with Fas (Ab-
1) diluted 100-fold and 10  L of protein A-agarose (Sigma,
U.S.A.). After incubation for 2 hr at 4℃, the pre-cleared ly-
sates were used for western blotting
Immunohistochemistry
The immunostaining for Fas and FasL were performed on
paraffin-embedded placental sections using Fas (Ab-1) and
anti-human Fas Ligand (Santa Cruz Biotechnology, Inc,
U.S.A.). Tissue sections were mounted on slides coated with
0.1% poly-L-lysine. After deparaffination and rehydration,
tissue sections were blocked with normal serum and incu-
bated for 1 hr with antibodies to Fas and FasL at a dilution
of 1:100. Tissue sections were treated in 0.1% Triton X-100
for 15 min and were incubated with a 1:1,000 diluted biotiny-
lated secondary antibody. After incubation in streptoavidin
buffer, the antibody complexes were visualized by incubation
with stable DAB chromogen (DAKO A/S, Denmark) for 5
min. Sections were counterstained with Autohematoxylin
(DAKO A/S, Denmark), dehydrated and mounted.
RESULTS
RT-PCR revealed amplified products of Fas (402 bp) (Fig.
1A) and FasL (407 bp) (Fig. 1B) transcripts along with
GAPDH (983 bp) transcripts in all placentas studied. The
levels of amplified Fas and FasL products, measured semi-
quantitatively by densitometry with reference to GAPDH,
were not different through gestation.
Immunoblotting showed multiple glycosylated bands of
FasL ranging from 42 to 52 kDa. A 26 kDa band, which
Fig. 1. RT-PCR amplification of Fas and FasL transcripts in hu-
man placenta. (A) RT-PCR reveals amplified products of Fas
(402 bp) and GAPDH (983 bp) transcripts. (B) RT-PCR reveals
amplified products of FasL (407 bp) transcripts and GAPDH
(983 bp) transcripts. J; Jurkat cell, T; trimester.
983 bp→
402 bp→
J 1 st T 2 nd T 3 rd T
983 bp→
407 bp→
1 st T 2 nd T 3 rd T
A
B
Fig. 2. Immunoblots for Fas and FasL in human placenta. (A) Im-
munoblot for Fas after preclearing with immunoprecipitation (IP)
reveals 52 kDa bands. (B) Multiple bands of glycosylated FasL
ranging from 42 to 52 kDa.
52 kDa →
IP precleared
52 kDa →
42 kDa →
1 st T 2 nd T 3 rd T
A
BFas and Fas Ligand in Human placenta 215
corresponds to soluble form of FasL, was observed after gly-
cosidase treatment of placental extracts. Densitometric mea-
surements of immunoblot revealed no significant change in
the level of FasL in placenta from the first trimester to the
third trimester of pregnancy (Fig. 2B). The presence of Fas
(52 kDa) in human placenta (15 placentas) was also con-
firmed by preclearing experiments with immunoprecipita-
tion (Fig. 2A).
Immunostaining of placenta from first trimester showed
localization of FasL in cytotrophoblastic cell column and
extravillous trophoblasts. In placenta from third trimester,
the staining for FasL, however, was observed mainly on syn-
cytiotrophoblast (Fig. 3B) and occasionally on intermediate
cytotrophoblast. On the other hand, the staining for Fas was
observed most strikingly in fetal vessels (Fig. 3A), notably
in degenerating villi and occasionally in intermediate tro-
phoblasts throughout gestation. The staining for Fas, how-
ever, was barely observed in syncytiotrophoblasts lining villi.
DISCUSSION
There are two potential sites of interaction between tro-
phoblastic cells and maternal lymphocytes in human pla-
centa (9). The first is the intervillous space where cells of
floating villi, consisting of an inner cytotrophoblastic layer
and an outer layer of syncytiotrophoblasts around a stromal
cell core, is bathed by maternal blood. The second site is the
placental bed where highly invasive extravillous cytotro-
phoblasts of the anchoring villi, known as intermediate tro-
phoblasts, invades deciduas and the first third of the myometri-
um. Fas-FasL system of trophoblast is located in these inter-
active sites and might play a role in maintaining pregnancy.
In the present study, we observed the expression of FasL
most prominently in syncytiotrophoblasts lining microvillar
membranes and less frequently in invasive extravillous cyto-
trophoblasts. Runic et al. (10) demonstrated the presence of
FasL in cytotrophoblasts of first trimester human placenta
and pronounced staining in syncytiotrophoblasts of term pla-
centa. Therefore, we speculate that in the first trimester of
pregnancy the main function of the Fas/FasL system, in this
area of the placenta, is more likely to be part of a mechanism
regulating placental growth than a strategy for immunolog-
ical defense. Furthermore, up to the 12th week of pregnancy,
maternal plasma alone was found in the intervillous space.
Only from the 13th week onwards does the intervillous space
contain maternal blood cell (11). Subsequent studies also con-
firmed the localization of FasL in syncytiotrophoblasts and
extravillous cytotrophoblasts by immunohistochemistry (8,
10) and in situ RT-PCR (12) techniques. Our results are con-
sistent with those previous reports in which FasL was detected
in trophoblastic cells, namely cytotrophoblasts and syncy-
tiotrophoblasts of placenta and support the concept that FasL
in syncytiotrophoblasts and extravillous cytotrophoblasts may
play a key role in maintaining immune privilege by repelling
the attack of activated maternal lymphocytes at intervillous
and placental bed sites.
In contrast to the localization of FasL in human placenta,
the expression of Fas was observed most strikingly in fetal
vessels, notably in degenerating villi and occasionally in
Fig. 3. Immunostainings for Fas and FasL in human placenta at term pregnancy. (A) The immunoreactivity for Fas is detected most
strikingly in fetal vessels. Note bare staining for Fas in syncytiotrophoblasts lining villi. (B) The immunostaining for FasL is observed
mainly on syncytiotrophoblast (original magnification ×200).
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intermediate trophoblastic cells. This may be the final protec-
tion from FasL expressing activated maternal T lymphocytes
in intervillous space. The expression of Fas, however, was not
evidently observed in syncytiotrophoblasts lining microvil-
lar membranes. In placenta, syncytiotrophoblasts are in direct
contact with maternal peripheral blood lymphocytes and FasL,
expressed in activated or cytotoxic T-lymphocytes, natural
killer cells and neutrophils, might bind to Fas on these target
cells and induces apoptosis (13, 14). Although it was report-
ed Fas- but not TNF receptor p55-mediated apoptosis was
blocked in primary villous trophoblasts (15), the bare stain-
ing for Fas in syncytiotrophoblasts seems to make sense in
that the Fas response may be avoided by FasL constitutively
expressed on neighboring cyto- or syncytiotrophoblasts and
activated maternal lymphocytes. The notable localization of
Fas in fetal vessels might have some clinical implications and
trophoblast apoptosis is a significant feature of early-onset
intrauterine growth restriction (16). It seems possible, in some
cases of intrauterine growth restriction, Fas mediated fetal
vascular apoptosis would be accentuated resulting in deficit
in peripheral villous development when orderly development
of the fetal villi is deranged by enhanced apoptosis of tropho-
blasts.
Our findings are different to data published for the term
placenta, where a constitutively high expression of Fas mRNA
and protein, and FasL mRNA and protein, was found in the
syncytiotrophoblast (12). In this study, we observed main
localization of Fas on fetal vessels and that of FasL on syncy-
tiotrophoblasts. The differential distribution of Fas and FasL
in human placenta can be explained by intrinsic expressions
of them in trophoblasts during differentiation. In patholog-
ic condition such as preeclampsia, the increased expression
of Fas in syncytiums may promote apoptosis of placenta.
The regulatory mechanisms for the expression of Fas and
FasL in human placenta, however, need further investigations.
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